



## FINANCIAL CONTRIBUTION AGREEMENT

This Financial Contribution Agreement (“Agreement”) is made between:

SANOFI A/S, a company duly organized under the laws of Denmark under the business identity number 19064301 and having its registered office located at Vibenshuset, Lyngbyvej 2, 2100 København Ø - Denmark (hereinafter referred to as “Sanofi”)

and

Eksemforening with chairperson Anne Vastrup, Hvidovrevej 108, 1. tv., 2650 Hvidovre, Denmark (“Recipient”)

### WHEREAS

- A. Sanofi is a diversified human healthcare Sanofi engaged in the research, design, development, production, marketing, distribution and sale of medicinal products and services;
- B. Recipient is Eksemforening with chairperson Anne Vastrup
- C. Recipient appointed Decisions, a company with registered address: Frederiksborggade 1A, 1.th.1360 København K, Danmark (“Organizer”), to take care of the execution of the disease awareness initiative empowering families living with atopic dermatitis to better understand and live with the disease. Sanofi will pay Decisions directly.

Recipient will use the funds to increase awareness of atopic dermatitis aimed at families with children suffering from the disease.

- D. Recipient has requested Sanofi for support in the project by means of a financial contribution and Sanofi has agreed to do so. The transfer of value from Sanofi to the individual associations is 84 000 DKK in total and the project will be executed by Decisions the agency of choice for Eksemforening for this project.

**NOW THEREFORE**, the parties hereto agree as follows:

### 1. Obligations of Sanofi

1.1 Subject to the terms and conditions of this Agreement, Sanofi shall support the Project by means of a financial contribution in the amount of 84 000 DKK. This contribution will be paid to Decisions – the agency of choice for this project by Eksemforening. The disease awareness initiative is co-sponsored by other pharma companies. The initiative is owned by the Recipient and produced and project managed in cooperation with the agency Decisions.

1.2 The Financial Contribution will be paid within 30 (thirty) calendar days following the receipt of an invoice, which is to be sent after the effective date of this Agreement.



1.3 Invoices must contain the following information:

- Sanofi name and address
- Sanofi's VAT registration number:
- Sanofi's Purchase Order number *PO number to be provided later*
- Invoice date
- Unique invoice number
- Recipient's bank account details
 

Bank Account Number
Name and Address of Bank
IBAN code
BIC / SWIFT code
- Any VAT references as required (Recipient is responsible for the correct VAT treatment)

1.4 Invoices should be sent by e-mail to [invoicesDK@sanofi.com](mailto:invoicesDK@sanofi.com) (one PDF or TIFF file per message) containing one request for payment and any attachments."

**2 Obligations of Recipient**

2.1 The Financial Contribution is given solely for the organization of the Project and shall not be used by Recipient for any other purpose without Sanofi's prior written consent.

A more detailed description of the Project, including a budget, is attached hereto as Exhibit A and B.

2.2 Recipient acknowledges the fact that Sanofi is a pharmaceutical company and can only financially support the Project if the Project as such meets the requirements of the EFPIA Member Association's Code of Practice in the country. In view thereof, Recipient represents and warrants that in the organization of the Project it shall abide by aforesaid requirements and, more generally, refrain from any acts and activities that (may) affect the legitimacy of Sanofi's Financial Contribution.

2.3 At Sanofi's request, Recipient shall fully disclose to Sanofi how the Financial Contribution has actually been spent.

2.4 Recipient shall clearly and legibly state in its communications related to the Project that the Project was 'made possible in part by Sanofi.

2.4 In return for the Financial Contribution provided by Sanofi, Recipient shall execute the disease awareness initiative as described in the application.

**3. Transparency**

3.1 Parties agree that the Financial Contribution made by Sanofi under this Agreement is subject to the provisions on disclosure of transfers of value between pharmaceutical companies, patient organizations and healthcare organizations as set forth in the EFPIA Member Association's Code of Practice in Recipient's country of registration (the "National Code of Practice").



3.2 Parties agree that Sanofi's local affiliate in Recipient's country of registration, Sanofi A/S Denmark, will take care of disclosure of the Financial Contribution in accordance with the relevant provisions of the National Code of Practice. To that end, Recipient hereby authorizes Sanofi to share with its local affiliate all information and details pertaining to Recipient and this Agreement as Sanofi's local affiliate may require for disclosure purposes in line with the National Code of Practice.

#### **4. Data Protection**

The Parties will process all personal data obtained during the term of this Agreement in accordance with applicable data protection laws and regulations including but not limited to the General Data Protection Regulation (EU) 2016/679 and its amendments.

#### **5. Compliance Undertakings**

5.1 Parties represent and warrant that

- in the execution of this Agreement they will comply with all applicable laws and (self-) regulations, including - but not limited to - the National Code of Practice (as defined in Article 3.2 above), data protection and anti-bribery legislation such as the UK Bribery Act 2010; and
- they, and where relevant, their directors, officers, employees, agents or subcontractors shall not, directly or indirectly pay or promise to pay, or authorize the payment of any money, or give, promise to give or authorize the giving of anything of value to any government official, healthcare professional or person affiliated with a healthcare organization to obtain or retain business or secure improper advantage to Sanofi.

5.2 Parties acknowledge that the Financial Contribution of Sanofi does not take effect and is not intended to take effect as an incentive or reward for Recipient's past, present or future willingness to prescribe, administer, recommend (including formulary recommendations), purchase, pay for, reimburse, authorize, approve or supply any product or service sold or provided by Sanofi or as an incentive to grant an interview for any sales or marketing purposes.

#### **6 Miscellaneous**

6.1 During the term of this Agreement and thereafter, each party shall keep in trust and confidence and not disclose to others all information it receives from the other party, provided however that these non-disclosure obligations do not apply to such (portion of) information that (i) at the time of disclosure is available in the public domain, (ii) after disclosure becomes available in the public domain through no fault of the receiving party, (iii) is required to be disclosed under applicable laws or (self-) regulations, including the National Code of Practice (as defined in Article 3.2 above), or (iv) is already in the possession of the other party.

6.2 This Agreement shall not be assigned or otherwise transferred by either party without the prior written consent of the other party; provided however that Sanofi may assign this Agreement to any of its affiliates or to a successor to its business (whether by merger, a sale of all or substantially all of its assets relating to this Agreement, a sale of its capital stock, or otherwise).




- 6.3 Either party may terminate this Agreement with immediate effect by written notice to the other party, if the other party commits a breach of this Agreement and the breach is not remedied within thirty (30) days after service of written notice requiring the same. If a party terminates this Agreement in accordance with this Article 6.3, the other party shall not be entitled to any compensation, indemnity or damages or other payment in respect of such termination. Article 3, Article 5.0, Articles 7.2 and 7.3 and all other provisions of this Agreement, including any Exhibit, that expressly or by their nature survive termination of this Agreement, shall continue in full force and effect subsequent to and notwithstanding such termination.
- 6.4 Sanofi shall have the right during the term of this Agreement and three (3) years thereafter to audit whether Recipient's use of the Financial Contribution is in accordance with this Agreement.

## 7. Effective Date, Governing Law and Dispute Resolution

- 7.1 This Agreement becomes effective when signed by an authorized representative of each party. A signed Agreement may be delivered by any reasonable means, including facsimile or other electronic transmission
- 7.2 The Agreement shall be governed by the laws of Denmark without reference to its conflict of laws provisions. The Parties shall try to solve by prior good faith negotiations any difficulties that may arise between them in the performance or construction of the Agreement. Should the Parties fail to reach an agreement, the Parties agree to submit the dispute to the exclusive jurisdiction of the competent court of Copenhagen, notwithstanding plurality of defendants, summary proceedings or impleader.

IN WITNESS WHEREOF, the Parties have duly executed this Agreement.

### SANOFI

Signature:   
 Birgitte Fyhn (Jul 10, 2025 09:36 GMT+2)

Date: 07/10/2025

Name: Birgitte Fyhn

Title: Head of Market Access & External Affairs Denmark

### Recipient

Signature\*:   
 Anne Skov Vastrup (Jul 9, 2025 23:06 GMT+2)

Date: 07/09/2025



---

Name: Anne Vastrup

---

---

Title: Chair Person, Eksemlforeningen

---

Exhibit A

**Anmodning om støtte til oplysningskampagne målrettet familier, hvor børn har atopisk eksem**

***Next step – en indsats for børnefamilier med atopisk eksem***

I 2024 fik Eksemlforeningen i samarbejde med Decisions og støttet af diverse medicinalvirksomheder udarbejdet en digital informationsfolder med information om atopisk eksem målrettet familier, hvor børn har atopisk eksem. Folderen kan ses på foreningens hjemmeside: [Atopisk\\_eksem\\_GUIDE\\_Digital.pdf](#)

Folderen indeholder relevant og opdateret information om atopisk eksem samt fungerer som opslagsværk, hvor man nemt kan finde specifikke emner. Desuden er der undervejs tilføjet referencer med links, så man har mulighed for at fordybe sig endnu mere i det ønskede emne. Vi er meget glade for denne ”dynamiske” folder.

Folderen er lavet, men der er behov for at få fortalt mange flere travle børnefamilier om det. Vi søger derfor støtte til en opfølgende oplysningskampagne såvel som lydbogsversion af folderen.

Vi har modtaget tilbud fra Decisions på ovenstående til i alt 250.000 kr. før moms.

Eksemlforeningen arbejder dog med budgetter i ”legoklods-format”, så projektet kan opstartes, selv om der ikke opnås fuld finansiering, da nogle af legoklodserne som f.eks. lydbogen er ønskede elementer, som evt. kan komme senere.

***Økonomisk anmodning***

Vi vil gerne samarbejde med Decisions om oplysningskampagne samt lade dem stå for fakturering og projektstyring.

Vi søger støtte hos AbbVie, LEO Pharma og Sanofi, og i forhåbning om at alle tre selskaber ønsker at bakke op, anmoder vi Sanofi om 84.000 kr. før moms til projektet, der samlet set lyder på 250.000 kr. før moms, jf. vedhæftede oplæg.

På forhånd mange tak for opbakningen til foreningens arbejde.

[Next%20step\\_En%20indsats%20for%20børnefamilier%20med%20atopisk%20eksem\\_20250425%20\(1\).pptx](#)

Exhibit B Budget

# Budgetskøn

Opgave:	Pris i alt DKK
Disease awareness kampagne	100.000
Projektledelse herunder rekruttering af og kontakt til børnefamilier og eksperter	10.000
Foto og videoptagelse	15.000
Klip og produktion	15.000
Indhold, design og grafik til SoMe-opslag	20.000
Mediekøb på sociale medier (tre måneder)	30.000
Opsætning og håndtering af mediekøb	10.000
Lydspor	25.000
Speak af publikation (podcastformat)	25.000
Pris i alt eksklusiv moms	250.000

# Eksemlforeningen om støtte til oplysningskampagne målrettet familier hvor børn har atopisk eksem next step Juli 2025

Final Audit Report

2025-07-10

Created:	2025-07-09
By:	Michaela Michaylova (Michaela.Michaylova@sanofi.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAA46sUmGW5G_EJcLGHwwlinG7nmPPWTWcQ
Documents:	Eksemlforeningen om støtte til oplysningskampagne målrettet familier hvor børn har atopisk eksem next step Juli 2025.pdf (6 pages)
Number of Documents:	1
Document page count:	6
Number of supporting files:	0
Supporting files page count:	0

## "Eksemlforeningen om støtte til oplysningskampagne målrettet familier hvor børn har atopisk eksem next step Juli 2025" History

 Document created by Michaela Michaylova (Michaela.Michaylova@sanofi.com)


Documents: Eksemlforeningen om støtte til oplysningskampagne målrettet familier hvor børn har atopisk eksem next step Juli 2025.pdf  
2025-07-09 - 9:45:31 AM GMT- IP address: 136.226.199.78

 Document emailed to anne@vastrup.dk for signature


2025-07-09 - 9:46:33 AM GMT

 Email viewed by anne@vastrup.dk

2025-07-09 - 10:20:08 AM GMT- IP address: 146.75.200.1

 Agreement viewed by anne@vastrup.dk


Documents: Eksemlforeningen om støtte til oplysningskampagne målrettet familier hvor børn har atopisk eksem next step Juli 2025.pdf  
2025-07-09 - 9:06:04 PM GMT- IP address: 147.78.31.31

 Signer anne@vastrup.dk entered name at signing as Anne Skov Vastrup

2025-07-09 - 9:06:50 PM GMT- IP address: 147.78.31.31

 Document e-signed by Anne Skov Vastrup (anne@vastrup.dk)

Documents: Eksemlforeningen om støtte til oplysningskampagne målrettet familier hvor børn har atopisk eksem next step Juli 2025.pdf  
Signature Date: 2025-07-09 - 9:06:52 PM GMT - Time Source: server- IP address: 147.78.31.31

 Document emailed to Birgitte Fyhn (birgitte.fyhn@sanofi.com) for signature

2025-07-09 - 9:06:53 PM GMT

 Email viewed by Birgitte Fyhn (birgitte.fyhn@sanofi.com)

2025-07-10 - 7:36:19 AM GMT- IP address: 155.117.35.228

 Agreement viewed by Birgitte Fyhn (birgitte.fyhn@sanofi.com)

Documents: Eksemforeningen om støtte til oplysningskampagne målrettet familier hvor børn har atopisk eksem next step Juli 2025.pdf

2025-07-10 - 7:36:20 AM GMT- IP address: 155.117.35.228

 Document e-signed by Birgitte Fyhn (birgitte.fyhn@sanofi.com)

Documents: Eksemforeningen om støtte til oplysningskampagne målrettet familier hvor børn har atopisk eksem next step Juli 2025.pdf

Signature Date: 2025-07-10 - 7:36:48 AM GMT - Time Source: server- IP address: 165.225.194.215

 Agreement completed.

2025-07-10 - 7:36:48 AM GMT